Skip to main content

New Additions to for 2024

The following 2 drugs were added to the database in 2024.

Feb 26, 2024 - Simlandi (adalimumab-ryvk) is a tumor necrosis factor (TNF) blocker interchangeable biosimilar to Humira, approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.

Feb 19, 2024 - Amtagvi (lifileucel) is a type of medicine called “tumor-derived autologous T cell immunotherapy” that is given as an infusion into your vein (usually in a hospital). It may be used to treat adults with melanoma that cannot be surgically removed or has spread to other parts of the body AND has not responded or has stopped responding to a PD-1 blocking drug either by itself or in a combination AND, if BRAF V600 mutation-positive, has not responded to a BRAF inhibitor with or without a MEK inhibitor.

Browse additions by year